Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases are characterized by chronic progressive degeneration of the structure and function of the nervous system, which brings an enormous burden on patients, their families, and society. It is difficult to make early diagnosis, resulting from the insidious onset and progressive development of neurodegenerative diseases. The drugs on the market cannot cross the blood-brain barrier (BBB) effectively, which leads to unfavorable prognosis and less effective treatments. Therefore, there is an urgent demand to develop a novel detection method and therapeutic strategies. Recently, nanomedicine has aroused considerable attention for diagnosis and therapy of central nervous system (CNS) diseases. Nanoparticles integrate targeting, imaging, and therapy in one system and facilitate the entry of drug molecules across the blood-brain barrier, offering new hope to patients. In this review, we summarize the application of iron oxide nanoparticles (IONPs) in the diagnosis and treatment of neurodegenerative disease, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). We focus on IONPs as magnetic resonance imaging (MRI) contrast agents (CAs) and drug carriers in AD. What most neurodegenerative diseases have in common is that hall marker lesions are represented by protein aggregates (Soto and Pritzkow, 2018). These diseases are of unknown etiology and unfavorable prognosis, and the treatments toward them are less effective (Soto and Pritzkow, 2018). Such diseases usually develop in aged people, and early clinical manifestations are atypical, resulting in difficulty in early diagnosis. Recently, nanomedicine has aroused considerable attention for therapy and diagnosis of CNS diseases because it integrates targeting, imaging, and therapy in one system (Gupta et al., 2019). In this review article, we first introduce the neurodegenerative diseases and commonly used MRI CAs. Then we review the application of IONPs in the diagnosis and treatment of neurodegenerative diseases with the purpose of assisting early theranostics (therapy and diagnosis).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180 · cited 2×
“These diseases are of unknown etiology and unfavorable prognosis, and the treatments toward them are less effective (Soto and Pritzkow, 2018).”
BackgroundIn vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
Adams, R. A., Bauer, J., Flick, M. J., Sikorski, S. L., Nuriel, T., Lassmann, H., Degen, J. L., & Akassoglou, K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061931 · Cited by 335
Wáng, Y. X. J., & Idée, J.-M. (2017) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2017.02.09 · Cited by 247
Research works printed but not linked: 59
- Akilo, 2016, AN in vitro evaluation of a carmustine-loaded Nano-co-Plex for potential magnetic-targeted intranasal delivery to the brain, Int. J. Pharm., 500, 196, 10.1016/j.ijpharm.2016.01.043 · DOI
- André, 2017, Validation by magnetic resonance imaging of the diagnostic potential of a heptapeptide-functionalized imaging probe targeted to amyloid-beta and able to cross the blood-brain barrier, J. Alzheimers Dis., 60, 1547, 10.3233/jad-170563 · DOI
- Ansciaux, 2015, In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer’s disease by molecular imaging, Contrast Media Mol. Imaging, 10, 211, 10.1002/cmmi.1626 · DOI · Paper page
- Anwar, 2014, Synthesis and in vitro localization study of curcumin-loaded SPIONs in a micro capillary for simulating a targeted drug delivery system, Int. J. Pharm., 468, 158, 10.1016/j.ijpharm.2014.04.038 · DOI
- Balestrino, 2019, Parkinson disease, Eur. J. Neurol., 10.1111/ene.14108 · DOI · Paper page
- Baloh, 2018, Stem cell transplantation for amyotrophic lateral sclerosis, Curr. Opin. Neurol., 31, 655, 10.1097/WCO.0000000000000598 · DOI
- Bigini, 2012, Longitudinal tracking of human fetal cells labeled with super paramagnetic iron oxide nanoparticles in the brain of mice with motor neuron disease, PLoS One, 7, e32326, 10.1371/journal.pone.0032326 · DOI
- Brambilla, 2011, Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues, Nanomedicine, 7, 521, 10.1016/j.nano.2011.03.008 · DOI · Paper page
- Busquets, 2014, Potential applications of magnetic particles to detect and treat Alzheimer’s disease, Nanoscale Res. Lett., 9, 538, 10.1186/1556-276x-9-538 · DOI · Paper page
- Canzi, 2012, Human skeletal muscle stem cell antiinflammatory activity ameliorates clinical outcome in amyotrophic lateral sclerosis models, Mol. Med., 18, 401, 10.2119/molmed.2011.00123 · doi:10.2119/molmed.2011.00123
- Chamberlain, 2009, Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer’s disease, Magn. Reson. Med., 61, 1158, 10.1002/mrm.21951 · DOI · Paper page
- Chandra, 2019, Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer’s disease and mild cognitive impairment, Hum. Brain Mapp., 40, 5424, 10.1002/hbm.24782 · DOI · Paper page
- Chen, 2019, Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric Aβ and tau species, Front. Neurosci., 13, 659, 10.3389/fnins.2019.00659 · DOI · Paper page
- Cheng, 2015, Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI), Biomaterials, 44, 155, 10.1016/j.biomaterials.2014.12.005 · DOI · Paper page
- Chung, 2018, Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson’s disease, Nanoscale, 10, 2998, 10.1039/c7nr06976f · DOI
- Corbett, 2012, New and emerging treatments for Alzheimer’s disease, Expert Rev. Neurother., 12, 535, 10.1586/ern.12.43 · DOI · Paper page
- De, 2011, Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications, Adv. Drug Deliv. Rev., 63, 1282, 10.1016/j.addr.2011.07.001 · DOI
- Dulińska-Litewka, 2019, Superparamagnetic iron oxide nanoparticles-current and prospective medical applications, Materials (Basel), 12, E617, 10.3390/ma12040617 · DOI · Paper page
- Fernández, 2018, Functionalization and characterization of magnetic nanoparticles for the detection of ferritin accumulation in Alzheimer’s disease, ACS Chem. Neurosci., 9, 912, 10.1021/acschemneuro.7b00260 · DOI · Paper page
- Gagliardi, 2019, Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature, Int. J. Mol. Sci., 20, E4152, 10.3390/ijms20174152 · DOI
- Giagkou, 2018, Therapeutic management of the overlapping syndromes of atypical Parkinsonism, CNS Drugs, 32, 827, 10.1007/s40263-018-0551-3 · DOI
- Glat, 2013, Age-dependent effects of microglial inhibition in vivo on Alzheimer’s disease neuropathology using bioactive-conjugated iron oxide nanoparticles, J. Nanobiotechnology, 11, 32, 10.1186/1477-3155-11-32 · DOI · Paper page
- Gupta, 2019, Nanoparticle formulations in the diagnosis and therapy of Alzheimer’s disease, Int. J. Biol. Macromol., 130, 515, 10.1016/j.ijbiomac.2019.02.156 · DOI · Paper page
- Ikenaka, 2019, Lipids as trans-acting effectors for alpha-synuclein in the pathogenesis of Parkinson’s disease, Front. Neurosci., 13, 693, 10.3389/fnins.2019.00693 · DOI
- Javdani, 2019, Effect of superparamagnetic nanoparticles coated with various electric charges on α-synuclein and β-amyloid proteins fibrillation process, Int. J. Nanomedicine, 14, 799, 10.2147/ijn.s190354 · DOI
- Jiang, 2017, Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe3O4 magnetic nanoparticles and BaYF5:Yb,Er nanoparticles as upconversion fluorescence labels, Talanta, 170, 350, 10.1016/j.talanta.2017.04.021 · DOI
- Jirak, 2019, Fluorine polymer probes for magnetic resonance imaging: quo vadis?, MAGMA, 32, 173, 10.1007/s10334-018-0724-6 · DOI
- Katebi, 2019, Superparamagnetic iron oxide nanoparticles combined with NGF and quercetin promote neuronal branching morphogenesis of PC12 cells, Int. J. Nanomedicine, 14, 2157, 10.2147/ijn.s191878 · DOI · Paper page
- Klohs, 2012, Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAβ mice, J. Neurosci., 32, 1705, 10.1523/jneurosci.5626-11.2012 · DOI · Paper page
- Kong, 2012, Magnetic targeting of nanoparticles across the intact blood-brain barrier, J. Control Release, 164, 49, 10.1016/j.jconrel.2012.09.021 · DOI · Paper page
- Kouyoumdjian, 2013, Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity, ACS Chem. Neurosci., 4, 575, 10.1021/cn3002015 · DOI · Paper page
- Li, 2019, Improving sensitivity and specificity of amyloid-β peptide and tau protein detection with anti-biofouling magnetic nanoparticles for liquid biopsy of Alzheimer’s disease, ACS Biomater. Sci. Eng., 5, 3595, 10.1021/acsbiomaterials.9b00086 · DOI · Paper page
- Ling, 2013, Chemical design of biocompatible iron oxide nanoparticles for medical applications, Small, 9, 1450, 10.1002/smll.201202111 · DOI · Paper page
- Mahmoudi, 2013, Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution, ACS Chem. Neurosci., 4, 475, 10.1021/cn300196n · DOI · Paper page
- Marasini, 2020, Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 12, e1580, 10.1002/wnan.1580 · DOI
- Mirsadeghi, 2016, Effect of PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) under magnetic field on amyloid β fibrillation process, Mater. Sci. Eng. C Mater. Biol. Appl., 59, 390, 10.1016/j.msec.2015.10.026 · DOI
- Niu, 2017, Inhibition by multifunctional magnetic nanoparticles loaded with α-synuclein RNAi plasmid in a Parkinson’s disease model, Theranostics, 7, 344, 10.7150/thno.16562 · DOI · Paper page
- Petiet, 2012, Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer’s transgenic mice, Neurobiol. Aging, 33, 1533, 10.1016/j.neurobiolaging.2011.03.009 · DOI
- Pillai, 2018, Rapidly progressive Alzheimer’s disease in two distinct autopsy cohorts, J. Alzheimers Dis., 64, 973, 10.3233/jad-180155 · DOI
- Poduslo, 2002, Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging, Neurobiol. Dis., 11, 315, 10.1006/nbdi.2002.0550 · DOI · Paper page
- Ramos-Gómez, 2015, Optimization of the magnetic labeling of human neural stem cells and MRI visualization in the hemiparkinsonian rat brain, J. Nanobiotechnology, 13, 20, 10.1186/s12951-015-0078-4 · DOI
- Rashid, 2016, Cyclen-based Gd3+ complexes as MRI contrast agents: relaxivity enhancement and ligand design, Bioorg. Med. Chem., 24, 5663, 10.1016/j.bmc.2016.09.069 · DOI
- Rotman, 2011, Pre-clinical optical imaging and MRI for drug development in Alzheimer’s disease, Drug Discov. Today Technol., 8, e117, 10.1016/j.ddtec.2011.11.005 · DOI
- Sachdeva, 2015, Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical evidence, Eur. J. Pharmacol., 747, 132, 10.1016/j.ejphar.2014.11.014 · DOI
- Salama, 2017, Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson’s disease, Exp. Ther. Med., 13, 976, 10.3892/etm.2017.4073 · DOI
- Sibov, 2014, Umbilical cord mesenchymal stem cells labeled with multimodal iron oxide nanoparticles with fluorescent and magnetic properties: application for in vivo cell tracking, Int. J. Nanomedicine, 9, 337, 10.2147/ijn.s53299 · DOI
- Sillerud, 2013, SPION-enhanced magnetic resonance imaging of Alzheimer’s disease plaques in AβPP/PS-1 transgenic mouse brain, J. Alzheimers Dis., 34, 349, 10.3233/jad-121171 · DOI · Paper page
- Skaat, 2013, Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-beta fibrils, Int. J. Nanomedicine, 8, 4063, 10.2147/ijn.s52833 · DOI
- Sonawane, 2019, Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer’s disease, ACS Omega, 4, 12833, 10.1021/acsomega.9b01411 · DOI · Paper page
- Sugaya, 2018, Stem cell therapies for neurodegenerative diseases, Adv. Exp. Med. Biol., 1056, 61, 10.1007/978-3-319-74470-4_5 · DOI
- Sun, 2016, Biodistribution of negatively charged iron oxide nanoparticles (IONPs) in mice and enhanced brain delivery using lysophosphatidic acid (LPA), Nanomedicine, 12, 1775, 10.1016/j.nano.2016.04.008 · DOI
- Tafoya, 2017, Superparamagnetic nanoparticle-enhanced MRI of Alzheimer’s disease plaques and activated microglia in 3X transgenic mouse brains: contrast optimization, J. Magn. Reson. Imaging, 46, 574, 10.1002/jmri.25563 · DOI
- Teleanu, 2019, Nanomaterials for drug delivery to the central nervous system, Nanomaterials (Basel), 9, E371, 10.3390/nano9030371 · DOI · Paper page
- Thomsen, 2015, Targeted drug delivery to the brain using magnetic nanoparticles, Ther Deliv, 6, 1145, 10.4155/tde.15.56 · DOI · Paper page
- Yang, Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease in vitro, ACS Chem. Neurosci., 2, 500, 10.1021/cn200028j · DOI · Paper page
- Yang, 2016, Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles, J. Nanobiotechnology, 14, 41, 10.1186/s12951-016-0198-5 · DOI
- Yarjanli, 2017, Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress and protein aggregation, BMC Neurosci., 18, 51, 10.1186/s12868-017-0369-9 · DOI · Paper page
- Zhang, 2015, The detection of beta-amyloid plaques in an Alzheimer’s disease rat model with DDNP-SPIO, Clin. Radiol., 70, 74, 10.1016/j.crad.2014.09.019 · DOI
- Zhou, 2014, Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer’s disease, Mater. Sci. Eng. C Mater. Biol. Appl., 37, 348, 10.1016/j.msec.2014.01.005 · DOI
Cited by
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Tomitaka, A., Vashist, A., Kolishetti, N., & Nair, M. (2023) · Nanoscale Advances · doi:10.1039/d3na00180f · Cited by 45
Yang, J., Luly, K. M., & Green, J. J. (2023) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1853 · Cited by 40
Unveiling the theranostic potential of SPIONs in Alzheimer's disease management
Aminyavari, S., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., Sanati, M., & Sahebkar, A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.09.022 · Cited by 5
Metadata
- Authors
- Luo, S., Ma, C., Zhu, M.-Q., Ju, W.-N., Yang, Y., & Wang, X.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2020-02-28
- Volume
- 14
- Pages
- 21-21
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W3008979652
- Cited by
- 109
- References
- 17
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Natural Science Foundation of China (81901083)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease. https://app.cochat.ai/papers/10.3389/fncel.2020.00021
- The paper
- Luo, S., Ma, C., Zhu, M.-Q., Ju, W.-N., Yang, Y., & Wang, X. (2020). Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2020.00021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.